Replies to post #322657 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Patent protection to 2030-2039, worldwide rights
for all product candidates

WORLDWIDE COMMERCIAL RIGHTS AND STRONG IP FOUNDATION
We retain global commercial rights to all of our product candidates and our lead product candidate, ANAVEX®2-73, including patent protection to 2030-2039

http://www.anavex.com/wp-content/uploads/2021/07/Anavex-Presentation-July-2021.pdf

Good luck and GOD bless,

[Investor2014]

Wasn’t missing. I said all along that Anavex have ways of navigating the imperfect A2-73 Plus patent protected only in the US and the lack of standalone patent for the original A2-73 formulation.

That navigation includes market exclusivity granted by the FDA and likely other agencies around the world.

Folks just seem frustrated about the IP risk as stated in every 10-K and don’t read before writing lots angry posts.

Pathetic.

[frrol]

No. It is not about who makes 2-73, it is about what we can currently do with it commercially, if approved, without being sued and by the holder of the worldwide single-use patent owner.